Cencora (NYSE:COR – Get Free Report) and Solventum (NYSE:SOLV – Get Free Report) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.
Insider & Institutional Ownership
97.5% of Cencora shares are held by institutional investors. 0.4% of Cencora shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations and price targets for Cencora and Solventum, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cencora | 0 | 3 | 12 | 0 | 2.80 |
| Solventum | 1 | 5 | 8 | 0 | 2.50 |
Profitability
This table compares Cencora and Solventum’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cencora | 0.78% | 135.20% | 4.20% |
| Solventum | 17.33% | 23.51% | 7.63% |
Risk and Volatility
Cencora has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Solventum has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Earnings & Valuation
This table compares Cencora and Solventum”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cencora | $321.33 billion | 0.17 | $1.55 billion | $13.04 | 21.63 |
| Solventum | $8.33 billion | 1.63 | $1.56 billion | $8.16 | 9.58 |
Solventum has lower revenue, but higher earnings than Cencora. Solventum is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
Summary
Cencora beats Solventum on 9 of the 14 factors compared between the two stocks.
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
